Pertuzumab Granted Priority Review for Neoadjuvant HER2-Positive Breast Cancer

Last week, the FDA announced that it would grant priority review to pertuzumab (Perjeta), as a neoadjuvant treatment for women with HER2-positive early-stage breast cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news